Literature DB >> 1250247

Mutagen specificity and position effects on mutation in T4rII nonsense sites.

A Ronen, A Rahat.   

Abstract

In 14 sites in the T4rII region, spontaneous and induced interconversions of ochre (UAA) and opal (UGA) alleles, as well as the reversion of the nonsense sites to r+, were studied. The mutagens employed were 2-aminopurine (2AP), 5-bromouracil (5BU), N-methyl-N'-nitro-N-nitrosoguanidine (NTG) and hydroxylamine (HA). With the test system employed, mutagen specificity (i.e., the preferential induction of A: T leads to G: C or G: C leads to A: T mutation at a given site) can be studied. Simultaneously, the response of similar base pairs at various locations in the same or in different nucleotide triplets throughout the rII region, to a given mutagen, can be compared. 2-Aminopurine can induce transitions of both A: T and G: C base pairs at high rates. This mutagen shows no preference for either direction. Furthermore, there is a correlation between the response to 2AP of an A: T pair occupying a given site, and that of a G: C pair occupying the same site. NTG and HA induce G: C leads to A: T transitions almost exclusively. However, there is a correlation between the low rates of A: T leads to G: C transition induced in each of the various sites by these mutagens and those of G: C leads to A: T. 5-Bromouracil induces transitions from G: C to A: T more readily than from A: T to G: C. With 5BU-induced mutation, there is no correlation between the rates of G: C leads to A: T transitions and those of A: T leads to G: C. In UAA sites, all three adenine:thymidine paris respond to 2AP mutagenesis in a similar pattern, In each position in the triplet, response to 2 AP is correlated with that to 5BU. In UGA sites, there are correlations among the spontaneous as well as the 2AP-, HA- and NTG-induced transition rates. 5BU-induced transition rates are usually not correlated with those induced by other mutagens or with the sponatneous ones.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1250247     DOI: 10.1016/0027-5107(76)90258-x

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  20 in total

1.  Mutation rates among RNA viruses.

Authors:  J W Drake; J J Holland
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  Experimental evolution recapitulates natural evolution.

Authors:  H A Wichman; L A Scott; C D Yarber; J J Bull
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-11-29       Impact factor: 6.237

3.  Template nucleotide moieties required for de novo initiation of RNA synthesis by a recombinant viral RNA-dependent RNA polymerase.

Authors:  M J Kim; W Zhong; Z Hong; C C Kao
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  A constant rate of spontaneous mutation in DNA-based microbes.

Authors:  J W Drake
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

5.  Templated mutagenesis in bacteriophage T4 involving imperfect direct or indirect sequence repeats.

Authors:  Gary E Schultz; John W Drake
Journal:  Genetics       Date:  2008-02-01       Impact factor: 4.562

Review 6.  DNA polymerase fidelity: from genetics toward a biochemical understanding.

Authors:  M F Goodman; K D Fygenson
Journal:  Genetics       Date:  1998-04       Impact factor: 4.562

7.  Bromouracil mutagenesis in Escherichia coli evidence for involvement of mismatch repair.

Authors:  B Rydberg
Journal:  Mol Gen Genet       Date:  1977-03-28

8.  Recombination in phage T4 gene-43 (DNA polymerase) mutants.

Authors:  A Ronen; C Halevy
Journal:  Mol Gen Genet       Date:  1979-01-11

9.  Mutagenesis of lambda phage: 5-bromouracil and hydroxylamine.

Authors:  F Hutchinson; J Stein
Journal:  Mol Gen Genet       Date:  1977-03-28

10.  Site specificity and variability in the mutator and antimutator effects of phage T4 gene 43 mutants.

Authors:  A Ronen; C Halevy; N Kass
Journal:  Genetics       Date:  1978-12       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.